TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Denali Therapeutics ( (DNLI) ) has issued an update.
On December 4, 2025, Denali Therapeutics entered into a $275 million synthetic royalty funding agreement with Royalty Pharma, which is contingent upon FDA approval of Denali’s investigational therapy, tividenofusp alfa, for Hunter syndrome. This agreement allows Denali to retain worldwide development and commercialization rights while providing Royalty Pharma a 9.25% royalty on future net sales, positioning Denali to advance its development programs and potentially transform treatment for Hunter syndrome.
The most recent analyst rating on (DNLI) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Denali Therapeutics stock, see the DNLI Stock Forecast page.
Spark’s Take on DNLI Stock
According to Spark, TipRanks’ AI Analyst, DNLI is a Neutral.
Denali Therapeutics faces significant financial hurdles with declining revenues and profitability issues, reflected in poor financial and valuation scores. Technical indicators also suggest a bearish trend. Positive corporate events, such as the BLA submission, offer a potential growth catalyst but are balanced by setbacks like the discontinued ALS trial. The overall outlook remains challenging, with strategic adjustments needed for improvement.
To see Spark’s full report on DNLI stock, click here.
More about Denali Therapeutics
Denali Therapeutics Inc. is a biotechnology company focused on developing biotherapeutics that can cross the blood-brain barrier using its proprietary TransportVehicle™ platform. The company is advancing a portfolio of therapeutic candidates aimed at treating neurodegenerative, lysosomal storage, and other serious diseases.
Average Trading Volume: 1,752,848
Technical Sentiment Signal: Buy
Current Market Cap: $2.62B
See more insights into DNLI stock on TipRanks’ Stock Analysis page.